SG11201700858RA - Adjunctive therapy with 25-hydroxyvitamin d - Google Patents

Adjunctive therapy with 25-hydroxyvitamin d

Info

Publication number
SG11201700858RA
SG11201700858RA SG11201700858RA SG11201700858RA SG11201700858RA SG 11201700858R A SG11201700858R A SG 11201700858RA SG 11201700858R A SG11201700858R A SG 11201700858RA SG 11201700858R A SG11201700858R A SG 11201700858RA SG 11201700858R A SG11201700858R A SG 11201700858RA
Authority
SG
Singapore
Prior art keywords
hydroxyvitamin
adjunctive therapy
adjunctive
therapy
Prior art date
Application number
SG11201700858RA
Inventor
P Martin Petkovich
Joel Z Melnick
Jay A White
Samir P Tabash
Charles W Bishop
Susan H Peers
Stephen A Strugnell
Original Assignee
Opko Ireland Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201700858R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Ireland Global Holdings Ltd filed Critical Opko Ireland Global Holdings Ltd
Publication of SG11201700858RA publication Critical patent/SG11201700858RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11201700858RA 2014-08-07 2015-08-06 Adjunctive therapy with 25-hydroxyvitamin d SG11201700858RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462034604P 2014-08-07 2014-08-07
PCT/EP2015/068219 WO2016020508A2 (en) 2014-08-07 2015-08-06 Adjunctive therapy with 25-hydroxyvitamin d

Publications (1)

Publication Number Publication Date
SG11201700858RA true SG11201700858RA (en) 2017-03-30

Family

ID=53783233

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201911274TA SG10201911274TA (en) 2014-08-07 2015-08-06 Adjunctive therapy with 25-hydroxyvitamin d
SG11201700858RA SG11201700858RA (en) 2014-08-07 2015-08-06 Adjunctive therapy with 25-hydroxyvitamin d
SG10201913853SA SG10201913853SA (en) 2014-08-07 2016-02-10 Adjunctive therapy with 25-hydroxyvitamin d and articles therefor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201911274TA SG10201911274TA (en) 2014-08-07 2015-08-06 Adjunctive therapy with 25-hydroxyvitamin d

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913853SA SG10201913853SA (en) 2014-08-07 2016-02-10 Adjunctive therapy with 25-hydroxyvitamin d and articles therefor

Country Status (23)

Country Link
US (7) US20180085381A1 (en)
EP (2) EP3193925A2 (en)
JP (6) JP2017523220A (en)
KR (2) KR20170047265A (en)
CN (3) CN106604733A (en)
AU (3) AU2015298858A1 (en)
BR (2) BR112017002526A2 (en)
CA (2) CA2957240A1 (en)
CL (2) CL2017000317A1 (en)
CO (2) CO2018004206A2 (en)
CR (3) CR20170085A (en)
EA (2) EA201790332A1 (en)
EC (2) ECSP17014159A (en)
HK (1) HK1258604A1 (en)
IL (3) IL250462A0 (en)
MX (3) MX2017001751A (en)
MY (1) MY194524A (en)
PE (2) PE20170392A1 (en)
PH (3) PH12017500228A1 (en)
SG (3) SG10201911274TA (en)
TW (2) TW202241453A (en)
UA (1) UA123947C2 (en)
WO (2) WO2016020508A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
PL2679228T3 (en) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
EP3542792B1 (en) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Controlled release 25-hydroxyvitamin d
ES2403107T3 (en) 2007-04-25 2013-05-14 Cytochroma Inc. Vitamin D insufficiency and deficiency treatment method
HUE048464T2 (en) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Methods and compositions for reducing parathyroid levels
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
CA2957240A1 (en) * 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
JP7032322B2 (en) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド Vitamin D treatment
DE102017110957A1 (en) * 2016-05-20 2017-11-23 Christoph Karl Zoledronic acid, calcium and vitamin D pharmaceutical compositions useful in the treatment and / or prophylaxis of bone metabolism disorders and therapy-induced hypocalcemia
DE102017110958A1 (en) * 2016-05-20 2017-11-23 Christoph Karl Pharmaceutical compositions containing anti-RANKL antibodies, calcium and vitamin D, useful in the treatment and / or prophylaxis of bone metabolism disorders and therapy-induced hypocalcemia
CN108519448B (en) * 2018-04-04 2021-04-13 北京市心肺血管疾病研究所 Application of 25-hydroxy vitamin D in preparation of disease activity evaluation kit for Takayasu arteritis patients
CN112912067A (en) * 2018-08-31 2021-06-04 欧普科爱尔兰环球控股有限公司 Pediatric dosage forms, methods of manufacture and use
KR20210126023A (en) * 2019-02-06 2021-10-19 에어젠 파마 엘티디. Methods for controlling the progression of hyperparathyroidism with calcifediol and compositions for use thereof
US20230293552A1 (en) * 2020-05-31 2023-09-21 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008517A2 (en) 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS55139320A (en) 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
JPS57188520A (en) 1981-05-15 1982-11-19 Kureha Chem Ind Co Ltd Antihyperkalemia
US4442093A (en) 1981-05-15 1984-04-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
JPS5832823A (en) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd Cancer eliminating agent
JPS58206524A (en) 1982-05-26 1983-12-01 Kureha Chem Ind Co Ltd Antitumor agent
US4448721A (en) 1982-09-20 1984-05-15 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 compounds and process for preparing same
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (en) 1983-02-22 1984-09-04 Teijin Ltd Active type vitamin d3 composition and its preparation
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
JPS61293911A (en) 1985-06-24 1986-12-24 Teisan Seiyaku Kk Sustained release preparation
US5167965A (en) 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4892821A (en) 1987-07-08 1990-01-09 Taisho Pharmaceutical Co., Ltd. Method for preparing vitamin D compounds
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
JP2893191B2 (en) 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
JP2525478B2 (en) 1989-03-01 1996-08-21 帝人株式会社 Active Vitamin D with improved stability (3) Lower solid preparation
JPH02240024A (en) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd Composition for active type vitamin d3s preparation
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (en) 1990-04-28 1999-01-13 大正製薬株式会社 Vitamin D Lower 3 Derivative-Containing Solid Preparation Composition
JPH04198129A (en) 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd Active type vitamin d>=3*s-containing composition
JP2893140B2 (en) 1990-11-30 1999-05-17 エスエス製薬株式会社 Stable vitamin D preparation
JPH04288016A (en) 1991-03-14 1992-10-13 Tokai Capsule Kk Production of soft capsule agent of active type vitamin d3s
CA2065603C (en) 1991-04-09 2007-04-03 Hiroki Itoh Stabilized vitamin d preparation
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DE69331409T2 (en) 1992-06-22 2002-08-29 Bone Care Internat Inc ORAL 1ALPHA HYDROXYPREVITAMIN D
US5354743A (en) 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (en) 1993-06-21 1997-12-03 呉羽化学工業株式会社 Inhibitor of bone loss in renal osteodystrophy
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (en) 1994-03-02 1995-09-19 Teijin Ltd Therapeutic agent for secondary hyperparathyroidism
IL110117A0 (en) * 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (en) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
CA2195623A1 (en) 1994-07-22 1996-02-08 Rajeev D. Gokhale Self-emulsifying drug delivery system
JPH0892098A (en) 1994-09-27 1996-04-09 Teijin Ltd Therapeutic medicine for consumption
BRPI9509411B8 (en) 1994-10-21 2021-07-06 Nps Pharma Inc inorganic ion receptor modulator compound and pharmaceutical composition
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
NZ319819A (en) 1995-09-21 2000-02-28 Wisconsin Alumni Res Found Calcitriol derivatives and their uses
DE19549243A1 (en) 1995-12-21 1997-06-26 Schering Ag Pharmaceutical preparations containing clathrates of cyclodextrins and unnatural vitamin D analogues
NO971934L (en) 1996-05-23 1997-11-24 Hoffmann La Roche Fluorinated vitamin D3 analogues
US5939408A (en) 1996-05-23 1999-08-17 Hoffman-La Roche Inc. Vitamin D3 analogs
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
JP2002511777A (en) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド Embedding and encapsulation of controlled release particles
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
JPH10158171A (en) 1996-12-02 1998-06-16 Kita:Kk Intraocular administrating agent formulating vitamin d compound therein
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
US5872113A (en) 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
JPH1175863A (en) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd 25-hydroxyvitamin d3-1-alpha-hydroxylase and dna encoding the same
US6096876A (en) 1997-08-06 2000-08-01 Shriners Hospitals For Children 1-α-hydroxylase materials and methods
AU9376998A (en) 1997-09-02 1999-03-22 Johns Hopkins University School Of Medicine, The Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US5919986A (en) 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
JPH11158074A (en) 1997-12-03 1999-06-15 Hayashi Tomie Amino acid-rich active vitamin d potentiation composition
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
EP1066377A1 (en) 1998-03-25 2001-01-10 Cutanogen, Inc. Methods for prevention and treatment of cancer
EP1064000B1 (en) 1998-03-27 2011-07-06 Oregon Health & Science University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US8133694B2 (en) 1998-06-25 2012-03-13 Immundiagnostik Ag Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
US6214376B1 (en) 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
SE9803871D0 (en) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
EA002720B1 (en) 1998-08-27 2002-08-29 Фармациа Энд Апджон Аб Therapeutic formulation for administering tolterodine with controlled release and method for treating urinary bladder using thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
CA2346001C (en) 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
ES2326502T3 (en) 1998-10-09 2009-10-13 General Mills, Inc. ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS IN A MATRIX TO OBTAIN DISCRETE PARTICLES OF LONG CONSERVATION.
JP3449253B2 (en) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 Manufacturing method of hard capsule
JP2000206312A (en) 1998-11-12 2000-07-28 Olympus Optical Co Ltd Optical element
IL143691A0 (en) 1998-12-17 2002-04-21 Alza Corp Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2274785T3 (en) 1999-04-01 2007-06-01 Johns Hopkins University ANALOGS OF 1-ALPHA, 25-DIHYDROXI VITAMIN D3 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE CONTAINING SULFUR.
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
DE19916419B4 (en) 1999-04-08 2005-06-16 Schering Ag Combination preparation of vitamin D metabolites or vitamin D analogues and an estrogen partial agonist for the treatment of osteoporosis
AU5139600A (en) 1999-05-27 2000-12-18 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6893658B1 (en) 1999-08-31 2005-05-17 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
JP2004504295A (en) 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド Stabilized 1α-hydroxyvitamin D
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
JP4596732B2 (en) 2000-08-29 2010-12-15 日新化成株式会社 Hard capsule
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
CN101317825A (en) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
JP2002302447A (en) 2001-04-03 2002-10-18 Shimizu Pharmaceutical Co Ltd Cancer therapeutic agent for topical administration
JP2004531548A (en) 2001-05-15 2004-10-14 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Compression method for the production of sodium phenytoin dosage form
CN100366239C (en) 2001-07-05 2008-02-06 涌永制药株式会社 Soft capsules
EP1416919A1 (en) 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US6870833B2 (en) 2001-07-20 2005-03-22 Net2Phone, Inc. Active voice messaging
US7166585B2 (en) 2001-08-22 2007-01-23 Cytochroma Inc. 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (en) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
WO2003031400A1 (en) 2001-10-12 2003-04-17 Johns Hopkins University Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (en) 2001-11-09 2003-05-09 Farmatron Ltd THERAPEUTIC SYSTEMS STABILIZED WITH IMMEDIATE RELEASE AND / OR MODIFIED FOR THE ORAL ADMINISTRATION OF ACTIVE AND / OR EXCIPIENT PRINCIPLES AND / OR WINGS
DE60238269D1 (en) 2001-11-22 2010-12-23 Morishita Jintan Co Non-gelatinous capsules
GB0128415D0 (en) 2001-11-27 2002-01-16 Univ Sheffield Medicaments
HUP0501186A2 (en) 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
FR2829142B1 (en) 2001-12-27 2004-02-13 Ulice FILMOGENEOUS COMPOSITION OF HETEROXYLANE FOR THE MANUFACTURE OF CAPSULES THUS OBTAINED
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (en) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysaccharide Capsules and Method of Preparation thereof
JP2005531532A (en) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Bone resorption inhibition method using alendronate and vitamin D preparation
NZ536267A (en) * 2002-04-10 2007-06-29 Fred H Miller Multi-phase, multi-compartment and multi-ingredient capsular system
CA2484244A1 (en) 2002-05-02 2003-11-13 Cytochroma Inc. Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof
EP1511725B1 (en) 2002-06-13 2012-02-01 Johns Hopkins University 24-sulfoximine vitamin d3 compounds
AU2003244840C1 (en) 2002-07-05 2010-03-04 Temrel Limited Controlled release composition
AR040672A1 (en) * 2002-07-25 2005-04-13 Glaxo Group Ltd MULTI-COMPONENT PHARMACEUTICAL DOSAGE FORM, PROPER BODY TO BE USED IN THE SAME AND PROCEDURE TO PREPARE IT
JP4500679B2 (en) 2002-07-29 2010-07-14 アルザ・コーポレーシヨン Methods and dosage forms for controlled delivery of paliperidone
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
WO2004028515A1 (en) 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (en) 2002-11-28 2004-06-24 Kose Corp Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
DE10393906T5 (en) 2002-12-16 2006-01-12 Teva Pharmaceutical Industries Ltd. A method of increasing the bioavailability of alendronate or another bisphosphonate by administering a pre-dose of a vitamin D derivative
DE20321698U1 (en) * 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. A medicament for increasing the bioavailability of alendronate or another bisphosphonate by administering a pre-dose of a vitamin D derivative
CA2510228C (en) 2002-12-18 2012-10-30 Johns Hopkins University 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3
DE602004015246D1 (en) 2003-02-11 2008-09-04 Alza Corp METHOD AND DOSAGE FORMS WITH MODIFIED LAYERING GEOMETRY
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
JP2006526057A (en) 2003-04-14 2006-11-16 エフ　エム　シー　コーポレーション Uniform and thermoreversible low viscosity polymannan gum film and soft capsule made therefrom
WO2004098507A2 (en) * 2003-04-30 2004-11-18 Bioxell S.P.A. 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
WO2004098617A2 (en) 2003-05-07 2004-11-18 Osteologix A/S Controlled release composition containing a strontium salt
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1638508B1 (en) 2003-06-16 2014-08-13 Solx, Inc. Shunt for the treatment of glaucoma
US8815284B2 (en) 2003-06-26 2014-08-26 Psivida Us, Inc. Bioerodible sustained release drug delivery systems
AU2003903382A0 (en) 2003-07-03 2003-07-17 Medvet Science Pty Ltd Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof
CA2531136A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
NZ545498A (en) * 2003-09-12 2010-04-30 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
WO2005051396A2 (en) 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
WO2005123120A1 (en) 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
WO2006007323A2 (en) 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
CN1993112A (en) 2004-07-29 2007-07-04 赛诺菲-安万特 Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
CN101316865B (en) 2004-12-03 2012-01-25 科学与工业研究委员会 Method for preparing biological degradable membrane from semi-refined kappa carrageen glycan
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
EP2985026B1 (en) 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (en) 2005-07-28 2007-08-08 Alza Corp LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
CN101273062A (en) 2005-09-29 2008-09-24 霍夫曼-拉罗奇有限公司 Antibodies against 25-hydroxyvitamin D
ITFI20050206A1 (en) 2005-09-30 2007-04-01 Valpharma Sa PHARMACEUTICAL COMPOSITION OF CONTROLLED RELEASE OF VENLAFAXINE CHLORIDRATE, AND PROCESS FOR ITS PREPARATION
ES2567595T3 (en) 2005-10-12 2016-04-25 Opko Renal, Llc Methods and articles to treat the insufficiency and deficiency of 25-hydroxyvitamin D
EP1959935A2 (en) 2005-10-26 2008-08-27 Banner Pharmacaps Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
US8293270B2 (en) 2005-10-26 2012-10-23 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
EP1954250A2 (en) 2005-11-01 2008-08-13 Andries Hanzen Films and capsules made from modified carboxymethycellulose materials and methods of making same
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
MXPA05014091A (en) 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Pharmaceutical compositions containing synthetic steroid derivatives such as tibolone, minerals such as calcium and the active metabolite of vitamin d (calcitrol) for the prevention and treatment of osteoporosis and menopause.
WO2007092221A2 (en) 2006-01-31 2007-08-16 Health Research Inc. Method for identifying altered vitamin d metabolism
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
GB0606426D0 (en) 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
JP2009540053A (en) 2006-06-06 2009-11-19 エフ エム シー コーポレーション Copper-2 carrageenan composition and products made therefrom
US20080109983A1 (en) 2006-11-10 2008-05-15 Kegel, Llc Zero Turning Radius Lane Maintenance Machine
PL2679228T3 (en) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
EP1912400A1 (en) 2006-10-10 2008-04-16 Matsushita Electric Industrial Co., Ltd. Method and apparatus for mobile IP route optimization
ES2895666T3 (en) 2006-10-27 2022-02-22 Capsugel Belgium Nv Hydroxypropylmethylcellulose hard capsules and manufacturing process
WO2008097646A1 (en) 2007-02-09 2008-08-14 Schering Corporation Methods to treat and/or prevent mucositis
US8491937B2 (en) 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
CN101682239A (en) 2007-03-20 2010-03-24 电锁公司 roebel winding with conductive felt
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP3542792B1 (en) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Controlled release 25-hydroxyvitamin d
ES2403107T3 (en) 2007-04-25 2013-05-14 Cytochroma Inc. Vitamin D insufficiency and deficiency treatment method
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
US20090004284A1 (en) 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
KR100836960B1 (en) 2007-09-07 2008-06-10 주식회사 서울제약 A novel controlled release-niacin formulation
EP2042165A1 (en) 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-melt filled soft capsules
US20090104206A1 (en) 2007-10-19 2009-04-23 Mark Zamoyski Bone microenvironment modulated migraine treatments
EP2229155A4 (en) 2007-12-12 2010-12-29 Northern Innovations And Formulations Corp Particles in a capsule
BRPI0907951A2 (en) * 2008-02-13 2015-08-04 Dsm Ip Assets Bv Combined use of 25-hydroxyvitamin d3 and vitamin d3 to improve bone mineral density and to treat osteoporosis
CN101951920A (en) 2008-02-13 2011-01-19 帝斯曼知识产权资产管理有限公司 Combination of vitamin D and 25-hydroxyvitamin D 3
PL2249842T3 (en) 2008-02-13 2017-01-31 Dsm Ip Assets B.V. Use of 25-hydroxy-vitamin d3 and vitamin d to affect human muscle physiology
KR20100117112A (en) 2008-02-13 2010-11-02 디에스엠 아이피 어셋츠 비.브이. Treating hypertension with 25-hydroxyvitamin d3
BRPI0907950A2 (en) 2008-02-13 2015-08-04 Dsm Ip Assets Bv Treatment of 25-hydroxyvitamin d3 hyperglycemia
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
JP2011518169A (en) 2008-04-15 2011-06-23 オステオジェネックス インコーポレイティド Compounds and methods for altering bone growth
ES2525180T3 (en) 2008-07-24 2014-12-18 Wisconsin Alumni Research Foundation Weekly administration of 25-hydroxy-vitamin D3 to maintain a blood concentration with high-steady-state pharmacokinetics
BRPI0823096B8 (en) 2008-09-24 2022-07-05 Evonik Roehm Gmbh pharmaceutical composition of a ph-dependent, controlled-release opioid with resistance against the influence of ethanol, process for its preparation, and its use
EP2179727B1 (en) 2008-10-27 2013-05-29 Roquette Freres Water insoluble polymer: modified starch derivative-based film coatings for colon targeting
BRPI1006902A2 (en) 2009-01-23 2016-02-16 Aziende Chimiche Riunte Angelini Francesco A C R A F S P A controlled release pharmaceutical or food formulation, process for producing a pharmaceutical or food form, controlled release system, and use of a controlled release system
CH700543A2 (en) 2009-03-03 2010-09-15 Innogel Ag Film based on starch.
KR101760534B1 (en) 2009-09-10 2017-07-21 에프엠씨 코포레이션 Seamless alginate capsules
IT1396937B1 (en) 2009-11-26 2012-12-20 Bruzzese FORMULATIONS OF BISPHOSPHONATES AND VITAMIN D SUITABLE FOR INTERMITTENT ADMINISTRATION BY INTRAMUSCULAR AND SUBCUTANEOUS
FR2953139B1 (en) 2009-11-27 2012-04-13 Servier Lab PHARMACEUTICAL COMPOSITION COMPRISING STRONTIUM SALT, VITAMIN D AND CYCLODEXTRIN
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
HUE048464T2 (en) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Methods and compositions for reducing parathyroid levels
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR20120005228A (en) * 2010-07-08 2012-01-16 주식회사 네비팜 An enteric pharmaceutical composition for the treatment of osteoporosis comprising bisphosphonate and the process thereof
US20130189522A1 (en) 2010-08-04 2013-07-25 R.P. Scherer Technologies, Llc Film-forming composition for soft capsules
US20130263297A1 (en) 2010-11-10 2013-10-03 Cedars-Sinai Medical Center Methods of treating cancer
US20120135103A1 (en) 2010-11-30 2012-05-31 Mead Johnson Nutrition Company Staged Infant Feeding Regimen To Promote Healthy Development And Growth
ES2712740T3 (en) 2010-12-06 2019-05-14 Dsm Ip Assets Bv Treatment of conditions associated with eotaxin increased with 25-hydroxyvitamin D3
AU2011353202B2 (en) 2010-12-28 2015-07-09 Future Diagnostics B.V. Release reagent for vitamin D
ES2641091T3 (en) 2011-03-02 2017-11-07 D3 Pharma Limited Vitamin D Composition
US8992971B2 (en) 2011-04-20 2015-03-31 Suheung Capsule Co., Ltd. Non-animal soft capsule shell composition having improved disintegration and shell hardness
EA201391553A1 (en) 2011-04-20 2014-03-31 Майко Байо, Инк. COMPOSITION AND METHOD OF STRENGTHENING IMMUNE RESPONSE
CN102771688A (en) 2011-05-13 2012-11-14 富曼实（上海）商贸有限公司 Edible liquid-filled polysaccharide capsule
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
SG11201408731WA (en) * 2012-06-29 2015-01-29 Wisconsin Alumni Res Found USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM
WO2014029953A1 (en) 2012-08-21 2014-02-27 Cipla Limited Hot melt extruded (hme) pharmaceutical composition of cinacalcet
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
PT106978A (en) 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A SOLID ORAL COMPOSITION CONTAINING IBANDRONIC ACID AND VITAMIN D
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103520133B (en) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 Preparation method of starch-based soft capsules
CN103495176B (en) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 Method for preparing starch-base soft capsules based on co-blending extrusion method
CA2957240A1 (en) 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d

Also Published As

Publication number Publication date
JP2021120370A (en) 2021-08-19
US20190142847A1 (en) 2019-05-16
US11738033B2 (en) 2023-08-29
ECSP18024971A (en) 2018-04-30
ECSP17014159A (en) 2017-05-31
AU2016325209B2 (en) 2022-04-14
EP3193925A2 (en) 2017-07-26
US20160038514A1 (en) 2016-02-11
US11007205B2 (en) 2021-05-18
WO2016020508A2 (en) 2016-02-11
IL258259A (en) 2018-05-31
AU2020267276A1 (en) 2020-12-10
PH12018500606A1 (en) 2018-10-01
EA201890812A1 (en) 2018-10-31
CL2018000739A1 (en) 2018-07-27
HK1258604A1 (en) 2019-11-15
WO2017050438A1 (en) 2017-03-30
TWI778934B (en) 2022-10-01
PH12020551759A1 (en) 2021-05-10
JP2017523220A (en) 2017-08-17
AU2016325209A1 (en) 2018-04-12
PE20181351A1 (en) 2018-08-22
US20210260079A1 (en) 2021-08-26
CN108135868A (en) 2018-06-08
CO2017002081A2 (en) 2017-07-19
PH12017500228A1 (en) 2017-07-03
JP2018534254A (en) 2018-11-22
US10220047B2 (en) 2019-03-05
NZ728823A (en) 2024-01-26
MX2018003698A (en) 2018-04-30
UA123947C2 (en) 2021-06-30
EP3352744A1 (en) 2018-08-01
BR112018006039A2 (en) 2018-10-09
JP2020203905A (en) 2020-12-24
CR20180228A (en) 2018-06-14
TW202241453A (en) 2022-11-01
TW201613607A (en) 2016-04-16
CL2017000317A1 (en) 2017-10-20
KR20170047265A (en) 2017-05-04
JP2023071723A (en) 2023-05-23
CA2998426A1 (en) 2017-03-30
CR20170085A (en) 2017-04-25
IL287698A (en) 2021-12-01
KR20180066108A (en) 2018-06-18
IL250462A0 (en) 2017-03-30
US20200253988A1 (en) 2020-08-13
US20180021354A1 (en) 2018-01-25
SG10201913853SA (en) 2020-03-30
CN106604733A (en) 2017-04-26
SG10201911274TA (en) 2020-02-27
JP2023002606A (en) 2023-01-10
MY194524A (en) 2022-11-30
CO2018004206A2 (en) 2018-09-20
AU2020267276B2 (en) 2022-12-08
CN114681468A (en) 2022-07-01
PE20170392A1 (en) 2017-04-07
WO2016020508A3 (en) 2016-03-31
US10493084B2 (en) 2019-12-03
KR102677359B1 (en) 2024-06-20
EA201790332A1 (en) 2017-06-30
JP7432069B2 (en) 2024-02-16
US20200101089A1 (en) 2020-04-02
BR112017002526A2 (en) 2017-12-05
MX2017001751A (en) 2017-05-30
CA2957240A1 (en) 2016-02-11
US20180085381A1 (en) 2018-03-29
MX2020011727A (en) 2022-05-24
AU2015298858A1 (en) 2017-03-02
CR20210577A (en) 2022-02-10
IL258259B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL287698A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
HUE051354T2 (en) Therapeutic
IL250387A0 (en) Combination therapy
IL257976A (en) Combination therapy
GB201516442D0 (en) Combination therapy
GB201405033D0 (en) Combination therapy
HK1255110A1 (en) Combination therapy
ZA201702522B (en) Combination therapy
GB201410216D0 (en) Therapeutic
EP3171876A4 (en) Combination therapy
GB201510637D0 (en) Therapeutic
GB201505382D0 (en) Novel therapy
ZA201608217B (en) Combination therapy
GB201414542D0 (en) Novel therapy
GB201518805D0 (en) Therapy
GB201419311D0 (en) Combination therapy
GB201506673D0 (en) Combination therapy
GB201410857D0 (en) Light therapy
GB201411570D0 (en) Therapy
GB201500681D0 (en) Combination therapy
GB201408210D0 (en) Therapy
GB201418508D0 (en) Therapeutic
GB201413719D0 (en) Therapeutic
GB201410832D0 (en) Therapeutic
GB201410334D0 (en) Therapeutic